BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

First Deal Under Business Development Push

 
• By Mandy Jackson
  
BioMarin is assessing several deals in addition to Inozyme (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Scrip